Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study

Hyun-Jun Kim,1 Youjin Kim,2 Su Jin Lee,2 Jeeyun Lee,2 Se Hoon Park2

1Department of Obstetrics and Gynecology, Konkuk University School of Medicine, Chungju, Korea
2Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

ABSTRACT

Objective: In the treatment of metastatic soft tissue sarcoma (STS), pazopanib is considered a standard treatment after failure of chemotherapy. We retrospectively investigated outcomes of pazopanib in patients with metastatic uterine STS.

Methods: A retrospective study was performed on 35 consecutive patients with uterine STS treated with oral pazopanib 800 mg daily as salvage therapy for metastatic disease between September 2013 and December 2015. Endpoints included response rate, survival, and safety.

Results: Among 35 patients, 27 (77%) had a histologic diagnosis of leiomyosarcoma (LMS) and the median age was 57 years (range, 36–70). Median number of metastatic sites was one (range, 1–5) with lung as the most frequently involved site. Pazopanib was generally well-tolerated: the major hematologic toxicity was grade 1/2 anemia (14%). Among the non-hematologic toxicities, grade 1/2 stomatitis was most commonly observed (22%), followed by fatigue and hypertension. Objective response and stable disease were observed in 10 (29%) and 11 (31%) patients, respectively. However, most cases of clinical response were observed in patients with LMS: 33% for LMS, 20% for undifferentiated pleomorphic sarcoma, and 0% for endometrial stromal sarcoma. Median progression-free and overall survivals were 5.8 months (95% confidence interval [CI]=3.6–8.1) and 20.0 months (95% CI=11.6–28.4), respectively.

Conclusion: In this “real-world” retrospective study, salvage therapy with pazopanib demonstrated clinically relevant efficacy and tolerability in unselected patients with uterine STS. Although it is encouraging that outcomes for Korean patients with uterine STS were similar to those reported in the phase III trial, the clinical benefit was limited to LMS.

Keywords: Sarcoma; Uterus; Endometrium; Pazopanib

INTRODUCTION

Uterine sarcoma is an uncommon and heterogeneous group of soft tissue sarcoma (STS) with aggressive clinical behavior and poor prognosis [1]. Leiomyosarcoma (LMS) is the most common histological subtype (60%), followed by endometrial stromal sarcoma (ESS), undifferentiated sarcoma, and others. When localized, complete surgical resection of tumors is the treatment of choice whatever the histologic subtype. However, since some patients present with primary metastatic disease and more than half of patients have recurrent
Funding
This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2017R1D1A3B04031900).

Conflict of Interest
No potential conflict of interest relevant to this article was reported.

Author Contributions
Conceptualization: K.H.J., P.S.H.; Data curation: K.Y., L.S.J., L.J.; Formal analysis: K.H.J., L.S.J., P.S.H.; Funding acquisition: K.H.J.; Investigation: K.H.J., L.S.J., P.S.H.; Methodology: K.Y., L.J.; Project administration: P.S.H.; Resources: K.Y., L.S.J., L.J., P.S.H.; Software: K.Y., L.S.J., L.J.; Supervision: P.S.H.; Validation: K.H.J., L.J., P.S.H.; Visualization: L.S.J., L.J.; Writing - original draft: K.H.J., K.Y.; Writing - review & editing: K.H.J., P.S.H.

Metastatic disease after surgery [2], the prognosis of uterine sarcoma remains poor. In metastatic setting, similar to other STS subtypes [3], conventional cytotoxic chemotherapy has shown modest activity against uterine sarcoma.

Pazopanib is an orally-administered, multi-targeted tyrosine kinase inhibitor (TKI) with a high affinity for vascular endothelial growth factor receptors (VEGFRs). Based on the results from a pivotal phase III trial [4], pazopanib is currently considered a standard treatment for patients with metastatic, non-adipocytic STS after failure of standard chemotherapy. The anti-tumor activity of pazopanib monotherapy was also evident in Korean STS patients in a retrospective study [5]. Because of oral administration and more favorable toxicity profiles, pazopanib is one of the most widely administered therapy in STS salvage setting. However, when it comes to metastatic uterine sarcoma, an aggressive disease that often shows rapid progression and clinical decline, the clinical trial population might not be indicative of all patients seen in daily oncology practice. When choosing a salvage treatment regimen for an individual patient, factors to be considered include the experiences of the treating oncologists, potential toxicity, especially for those with symptoms or with decreased performance status, as well as the activity of chemotherapeutic agents. Based on these considerations, we designed this single-center, retrospective study to evaluate the efficacy and safety of pazopanib monotherapy in heavily-pretreated, Korean patients with metastatic uterine sarcoma.

MATERIALS AND METHODS

We retrospectively collected and reviewed medical records of 35 adult patients with uterine STS who were consecutively treated with pazopanib (Votrient; GlaxoSmithKline, Research Triangle Park, NC, USA) as salvage therapy in between September 2013 and December 2015. Patients enrolled in clinical trials were excluded to ensure the study population reflected our daily clinical practice, and the choice of pazopanib was solely at the discretion of the treating oncologists. Other exclusion criteria for case inclusion were as follows: 1) absence of measurable metastatic disease, 2) histologic diagnosis of osteosarcoma, chondrosarcoma, liposarcoma, Ewing’s sarcoma, primitive neuroectodermal tumor, or other excluded subtypes in the pazopanib phase III trial [4], 3) another malignancy within 5 years, and patients with inappropriate laboratory findings or severe comorbid illness for standard 800 mg per day dose of pazopanib. Institutional Review Boards approval was obtained from Samsung Medical Center (SMC; Seoul, Korea). Written informed consent was given by all patients prior to starting pazopanib, according to institutional standards.

In all patients, pazopanib at a starting dose of 800 mg per day was administered orally without interruption. Supportive care including the administration of blood products, and the use of analgesics was given if judged appropriately by the treating physicians. Before initiating the first dose of pazopanib, patients had a complete history taken, complete blood counts and serum chemistries, chest X-rays, and computed tomography scans of all involved sites. Patients were seen every 4 weeks as pazopanib therapy was repeated every 4 weeks. Therapy was continued until objective disease progression per Response Criteria in Solid Tumours (RECIST) [6], unacceptable toxicity or deterioration of hepatic function, or patient refusal. Dose adjustments at the start of a new cycle were based on the worst toxicity observed during the previous cycle. Baseline characteristics and outcome data were collected using a uniform case report form. Clinical and laboratory parameters collected at the time of starting pazopanib included age,
Eastern Cooperative Oncology Group (ECOG) performance status, histological grade according to Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC), site(s) of metastases, previous surgery and/or radiotherapy, and previous chemotherapeutic regimens. Responses were evaluated every 8 weeks by chest and abdominopelvic computed tomography or by the same tests that were used to stage initial tumors. Adverse events were collected and graded according to the National Cancer Institute criteria (Common Terminology Criteria for Adverse Events [CTCAE] v4). To determine the causes of death, as well as therapy discontinuation, a structured medical record review was performed.

The primary end point was the response rate (RR). Secondary end points included progression-free survival (PFS), overall survival (OS), and a toxicity profile. Time from the first day of pazopanib administration to death, whatever the cause, was used to calculate OS. PFS and OS were calculated using the Kaplan-Meier method. To examine the impact of baseline parameters collected on PFS and OS, Cox proportional hazard model was used. Laboratory parameters and age were initially recorded as continuous variables, and evaluated as both continuous and categorical variables. The potential presence of interaction effects between baseline parameters was tested by defining product terms for the respective factors in a regression model. All p-values were 2-sided, with p<0.05 indicating statistical significance. All analyses were performed using the R for Windows v2.11.1 software (R Core Team, Vienna, Austria; http://www.Rproject.org).

RESULTS

The SMC cancer chemotherapy registry identified 35 eligible patients who were treated with salvage pazopanib for metastatic STS of uterine origin. Patient characteristics are given in Table 1. As shown, their median age was 57 years (range, 36–70). Approximately 77% of patients had a histologic diagnosis of LMS, followed by undifferentiated pleomorphic sarcoma (UPS), ESS, and undifferentiated sarcoma. Patients with ESS (n=3) had a high-grade (FNCLCC grade 3/3) tumor. All patients were heavily pretreated, as half of them had received 2 or more chemotherapy regimens. Because of the lack of a standard therapy for STS, prior chemotherapy regimens included etoposide/ifosfamide/cisplatin (n=15), docetaxel/gemcitabine (n=14), doxorubicin monotherapy (n=9), doxorubicin/cisplatin (n=7), ifosfamide monotherapy (n=6), and doxorubicin/ifosfamide (n=4). Most commonly involved site of metastases was lung, retroperitoneum, and/or peritoneum. At the time of data collection, with a median follow-up duration of 34 months, 29 patients developed disease progression and 22 had died.

A total of 229 4-week pazopanib cycles were administered (median 4, range 1–24). The most common reason for therapy discontinuation was disease progression (80%). Overall, oral pazopanib was generally well tolerated, with hypertension, stomatitis, fatigue and grade 1 or 2 anemia being the most commonly observed toxicities (Table 2). Transient and reversible liver function test elevation was observed in 5 patients. No treatment-related deaths were identified.

Of a total of 35 patients, one patient could not be evaluated for clinical responses because of early discontinuation of therapy. Objective responses to pazopanib were noted in 10 patients (RR=29%; 95% confidence interval [CI]=14%–44%), including one complete response. Stable disease was observed in 11 patients (31%), leading to a 60% disease control rate (Fig. 1). Patients who had a LMS histology were, although statistically insignificant (p=0.80), more likely to
respond to pazopanib (9/27, 33%) compared to those with UPS (1/3, 33%) or ESS (0%). In addition, to explore predictive factors for clinical response to pazopanib, we performed a logistic regression analysis with known baseline parameters. As a result, RR was not significantly influenced by histologic subtypes (LMS vs. non-LMS; odds ratio [OR]=0.79; 95% CI=0.13–4.79; p=0.79), age (>median vs. ≤median; OR=0.91; 95% CI=0.19–4.48; p=0.91), performance status (0 vs. 1; OR=0.78; 95% CI=0.18–3.42; p=0.74), FNCLCC grade (1 or 2 vs. 3; OR=0.58; 95% CI=0.14–2.50; p=0.46), number and site of metastases, or baseline laboratory parameters. We

| Characteristics | No. of patients (%) |
|-----------------|---------------------|
| **Age (yr)**    |                     |
| Median (range)  | 57 (36–70)          |
| **Histology**   |                     |
| LMS             | 27 (77)             |
| UPS             | 3 (9)               |
| ESS             | 3 (9)               |
| Undifferentiated| 2 (6)               |
| **Tumor grade** |                     |
| 1               | 8 (23)              |
| 2               | 10 (29)             |
| 3               | 17 (49)             |
| **ECOG performance status** |                 |
| 0               | 10 (29)             |
| 1               | 25 (71)             |
| **Metastatic sites** |                 |
| Lung            | 22 (63)             |
| Lymph node(s)   | 9 (26)              |
| Bone            | 8 (23)              |
| Liver           | 9 (26)              |
| Retroperitoneum and/or peritoneum | 15 (43) |
| **Previous treatment** |                 |
| Surgery         | 31 (89)             |
| Radiotherapy    | 14 (40)             |
| **No. of prior chemotherapy** |                |
| One             | 17 (49)             |
| Two or more     | 18 (51)             |
| **Prior chemotherapeutic regimens** |              |
| Doxorubicin     | 21 (60)             |
| Ifosfamide      | 26 (74)             |
| Platinum        | 21 (60)             |
| Taxanes         | 14 (40)             |

ECOG, Eastern Cooperative Oncology Group; ESS, endometrial stromal sarcoma; LMS, leiomyosarcoma; UPS, undifferentiated pleomorphic sarcoma.

**Table 2. Maximum grade toxicity recorded per patient (n=35)**

| Toxicities       | Grade 1–2 | Grade 3–4 |
|------------------|-----------|-----------|
| Anemia           | 7 (20)    | 1 (3)     |
| Neutropenia      | 2 (6)     | 0         |
| Thrombocytopenia | 5 (14)    | 0         |
| Nausea           | 3 (9)     | 0         |
| Vomiting         | 2 (6)     | 0         |
| Anorexia         | 6 (17)    | 0         |
| Stomatitis       | 8 (23)    | 2 (6)     |
| Diarrhea         | 6 (17)    | 1 (3)     |
| Fatigue          | 7 (20)    | 1 (3)     |
| Skin             | 6 (17)    | 0         |
| Hepatic          | 5 (14)    | 0         |
| Hypertension     | 19 (54)   | 0         |

Values are presented as number of patients (%).
also tested whether the development of clinical responses was modified by interaction between the effects of parameters; the first-level interaction term between these variables was entered into separate multivariate model but we found no interaction between them.

The estimated median PFS and OS were 5.8 months (95% CI=3.6–8.1) and 20.0 months (95% CI=11.6–28.4), respectively (Fig. 2). In contrast to RR, within the limitation of small sample size, the estimated PFS (median 5.8 months, 95% CI=2.5–9.1 vs. 3.0 months, 95% CI=0–7.6; p=0.680) as well as OS (20.0 months vs. not reached; p=0.404) were similar between patients with LMS and ESS or other histologic subtypes, respectively (Fig. 3). In the Cox regression model, the estimated PFS or OS was not significantly influenced by any of the baseline parameters. After pazopanib failure, half (49%) of the patients received further lines of therapy, mostly with taxane-based (n=14) and clinical trials with novel agents (n=10). For exploratory purposes, we then compared OS between patients who received further therapy

---

Fig. 1. Forest plot showing maximum tumor shrinkage to pazopanib treatment.

Fig. 2. OS (solid line) and PFS (dotted line) of all patients.
OS, overall survival; PFS, progression-free survival.
after pazopanib failure and who did not. Although statistically insignificant, those who received further lines of therapy lived longer (27.4 vs. 8.6 months, p=0.156).

DISCUSSION

This retrospective study on a limited number of patients showed that the salvage therapy with pazopanib in Korean patients with uterine STS can be both well tolerated and active, regardless of their performance status or the number of metastases. The estimated median PFS and OS were 5.8 months (95% CI=3.6–8.1) and 20.0 months (95% CI=11.6–28.4), respectively. Most cases of adverse events were transient and self-limited. In addition, there were few severe non-hematologic toxicities, with grade 3 or 4 stomatitis or diarrhea in only 3%–6% of patients. The results compared favorably with outcomes obtained in prospective clinical trials [2,4], as well as a Korean retrospective study [5]. However, the clinical benefit with pazopanib was limited to patients with LMS. In those with uterine LMS, pazopanib achieved objective response in 33% of patients, whereas 13% in other histologic subtypes.
Although this study is retrospective in nature and has a limited number of patients, our results seem to suggest that patients with uterine STS other than LMS may not derive clinically relevant benefit from treatment with pazopanib.

Uterine STS is an uncommon but aggressive mesenchymal tumor. Because of the relative rarity of uterine STS, clinical decision making depends on data available for STS arising from other primary sites [7]. In metastatic setting, active agents against STS include doxorubicin, ifosfamide, taxanes, gemcitabine, and trabectedin. Pazopanib, an orally-administered VEGFR TKI, has been the mainstay of therapy in the treatment of non-adipocytic STS patients failing prior chemotherapy, on the basis of the prospective phase II and III trials [2,4]. These 2 clinical trials included a total of 44 patients with uterine STS, and the results of a subgroup analyses was recently published [8]. Although the authors concluded that the clinical efficacy of pazopanib in patients with uterine STS was comparable to those with non-uterine STS, a majority (89%) of patients had LMS histology. In the present study, we observed that other subtypes of uterine STS than LMS, ESS or undifferentiated sarcoma in particular, did not respond to pazopanib. These histologic subtypes probably differ both clinically and biologically, but it remains unknown if there are any clinical or biologic characteristics that would result in pazopanib unresponsiveness.

The best choice of treatment regimen for patients with metastatic STS is still a matter of controversy and requires careful considerations of individual patient’s disease status, symptoms, general condition, and histologic subtype. In first-line setting, the decision to use chemotherapeutic agents, alone or in combination should be determined by their relative merits on a case-by-case basis [3,9]. More recently, more than a few targeted agents have shown promising results in patients with metastatic STS. In addition to pazopanib, a novel monoclonal antibody olaratumab that blocks platelet-derived growth factor receptor (PDGFR) showed improved survival when combined with doxorubicin [10]. Although we do not know how many patients with uterine STS were included in the olaratumab trial, the subsequent phase III trial (ANNOUNCE; ClinicalTrials.gov, NCT02451943) is under way so that the final results are awaited.

The strength of this study includes its single-center nature with patients who were treated with pazopanib as a routine clinical practice to avoid selection bias. It should be noted that the patients included in this study are consecutive series of patients taken from an academic, tertiary cancer center to reflect the real-world experience of salvage pazopanib. This indeed may differ from clinical trial patients, which is more relevant to the clinician’s daily practice. That is, the study reflects real-world outcomes that may not necessarily be seen in randomized controlled trials with selected patients. On the other hand, limitations of this study include its retrospective nature, which may predispose the study to selection bias and issues with missing data. Selection bias can be minimized by obtaining consecutive series of patients as seen in the current results. The lack of central radiology review, variable modalities of imaging, and intervals between scans were potential weaknesses; however, we believe it better reflects the real-world experience of oncologists treating patients with uterine STS.

In conclusion, results obtained in the present study suggest that pazopanib is an active and safe regimen for the salvage therapy of Korean patients with uterine STS. Although it is encouraging that OS and PFS for Korean patients with uterine STS were similar to those reported in the phase III trial, the clinical benefit was limited to those with LMS. With better patient selection, clinical outcomes of patients with pretreated, metastatic, uterine STS can be improved.
ACKNOWLEDGMENTS

We thank all the participating researchers for making this study possible.

REFERENCES

1. Kummar S, Allen D, Monks A, Polley EC, Hose CD, Ivy SP, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol 2013;31:2296-302.

2. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J Clin Oncol 2009;27:3126-32.

3. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007;25:144-50.

4. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86.

5. Yoo KH, Kim HS, Lee SJ, Park SH, Kim SJ, Kim SH, et al. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC Cancer 2015;15:154.

6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.

7. El-Khalfaoui K, du Bois A, Heitz F, Kurzeder C, Sehouli J, Harter P. Current and future options in the management and treatment of uterine sarcoma. Ther Adv Med Oncol 2014;6:21-8.

8. Benson C, Ray-Coquard I, Sleijfer S, Litière S, Blay JY, Le Cesne A, et al. Outcome of uterine sarcoma patients treated with pazopanib: a retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. Gynecol Oncol 2016;142:89-94.

9. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-45.

10. Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase Ib and randomised phase 2 trial. Lancet 2016;388:488-97.